Global Automated and Closed Cell Therapy Processing Systems Market: Current Analysis and Forecast (2022-2028)

Cell Therapy is a type of therapy, where viable cells are insinuated, grafted, or injected into a patient to create a medicinal effect. It is a technology that relies on replacing diseased or dysfunctional cells with healthy, functioning ones. The rising popularity of regenerative medication, as well as the expansion of the GMP manufacturing facilities, is attributed to the market growth of automated and closed-cell therapy processing systems. Furthermore, the integration of automation and software technologies with cell therapy is also expected to propel the market growth of automated and closed-cell therapy process systems.

The Automated and Closed-Cell Therapy Process Systems Market is expected to grow at a steady rate of around 21% owing to the frequent product launches. For instance, in October 2019, Terumo launched a cell therapy production-specific automation device which is developed to bring reproducibility and control to cell therapy manufacturing.

Based on the workflow, the market has been categorized into separation, expansion, apheresis, fill-finish, cryopreservation, and others. Among them, the expansion segment holds a considerable share of the market. The increasing focus on achieving high output, along with the surging adoption of the expansion systems by the market players attributes to a significant share of the segment in the automated and closed cell therapy processing systems market.

Based on the type, the market has been categorized into stem cell therapy and non-stem cell therapy. Among them, the non-stem cell therapy segment is expected to grow at a higher CAGR in the market. The surging prevalence of cancer and the high success rate of non-stem cell therapy such as CAR-T therapy in the treatment of cancer attributes to the fastest growth of the segment. However, stem cell therapy is also expected to hold a considerable share due to rising awareness about the benefits offered by stem cell therapy, and rising research efforts in the development of better stem cell treatment.

Based on the scale, the market has been categorized into pre-commercial/ R&D scale and commercial scale. Among them, the pre-commercial/ R&D scale category is to witness higher adoption of automated and closed cell therapy processing systems during the forecast period. The increasing demand for cell therapy due to the rising incidences of chronic diseases, as well as the increasing clinical trials, is attributed to the high share of the pre-commercial segment.

For a better understanding of the market adoption of the automated and closed-cell therapy process systems industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America is anticipated to hold a considerable market share during the forecast period. This is mainly due to the increasing presence of well-established market players in the region, advancements in cell therapy, and the growing population with an increasing number of cancer cases. For instance, according to the American Cancer Society (CMS), in 2022, around 99,780 new melanomas were diagnosed. About 7,650 people are expected to die of melanoma in the U.S. Moreover, the availability of major key players and manufacturers progressively increases its capacity to meet the growing global demand for automated and closed-cell therapy process systems.

Some of the major players operating in the market are Miltenyi Biotec; Lonza; Fresenius Kabi AG; Danaher; BioSpherix, Ltd; Terumo Corporation; Sartorius AG; ThermoGenesis Holdings, Inc.; Cellares Inc.; and Thermo Fisher Scientific.